Daytime administration may reduce the risk of nocturnal hypoglycemia and align better with patients' routines, while nighttime administration provides stable overnight insulin levels and helps control fasting glucose [3]. Studies have shown that maintaining a consistent timing of Gla-300 administration, whether in the morning or evening, results in stable glycemic control. The gene discussed is INS; the disease is Hypoglycemia.